Countdown begins for 3rd generation lung cancer drugs among Hanmi, BI and AZ

Competed by Hanmi Pharm, Boehringer Ingelheim and AstraZeneca, launches of the 3^rd generation non-small cell lung cancer treatments have begun a countdown.

According to the Ministry of Food and Drug Safety(MFDS) and a person concerned to Hanmi Pharm on the 24^th, the Hanmi Pharm’s 3^rd generation lung cancer drug, ‘HM61713’ is expected to acquire commercialization approval within the first half...